Atomo DiagnosticsASX:AT1 ROE % is -51.84% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Atomo Diagnostics ranks worse than 84.11% on this metric.
The historical rank and industry rank for Atomo Diagnostics's ROE % or its related term are showing as below:
ASX:AT1'
s ROE % Range Over the Past 10 Years
Min: -58.27 Med: -38.51 Max: -18.65
Current: -56.74
During the past 6 years, Atomo Diagnostics's highest ROE % was -18.65%. The lowest was -58.27%. And the median was -38.51%.
ASX:AT1's ROE % is ranked worse than 84.11% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs ASX:AT1: -56.74
Atomo Diagnostics (ASX:AT1) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Atomo Diagnostics ROE % Related Terms
Atomo Diagnostics ROE % Historical Data
* Premium members only.
The historical data trend for Atomo Diagnostics's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Atomo Diagnostics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atomo Diagnostics ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Atomo Diagnostics's ROE % distribution charts can be found below:
* The bar in red indicates where Atomo Diagnostics's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Atomo Diagnostics (ASX:AT1) has a ROE % of -51.84% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Atomo Diagnostics and its competitors. According to the industry distribution chart, Atomo Diagnostics ranks #672 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 84.1%.
Is Atomo Diagnostics' ROE % too high?
Atomo Diagnostics' current ROE % is -51.84%. Based on the distribution chart, Atomo Diagnostics ranks #672 out of 799 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Atomo Diagnostics' ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Atomo Diagnostics ranks #672 out of 799 companies for ROE %. This places Atomo Diagnostics in the lower half of its industry. The industry median ROE % is 2.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Atomo Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atomo Diagnostics's current ROE % is -51.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 15% below its estimated fair value. The current ROE % is -51.84%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current ROE % is -51.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AT1 has been successfully added to your 